Gyre Therapeutics (GYRE) Notes Payables (2015 - 2017)

Gyre Therapeutics (GYRE) has 3 years of Notes Payables data on file, last reported at $5.1 million in Q4 2017.

• Notes Payables for Q4 2017 came in at $5.1 million, down 73.79% year-over-year; the trailing twelve-month figure through Dec 2017 was $5.1 million (down 73.79% YoY), and the FY2017 annual result was $5.1 million, down 73.79% from the prior year.
• Notes Payables fell to $5.1 million in Q4 2017 per GYRE's latest filing, from $5.5 million in the prior quarter.
• Over five years, Notes Payables peaked at $34.8 million in Q3 2015 and troughed at $5.1 million in Q4 2017.
• A 3-year average of $20.8 million and a median of $24.5 million in 2016 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2016 and 2017: Notes Payables declined 14.69% in 2016, then plunged 81.5% in 2017.
• A 3-year view of Notes Payables shows it stood at $33.7 million in 2015, then sank by 42.5% to $19.4 million in 2016, then plunged by 73.79% to $5.1 million in 2017.
• Business Quant data shows GYRE's Notes Payables at $5.1 million in Q4 2017, $5.5 million in Q3 2017, and $5.8 million in Q2 2017.